S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.70 (+2.38%)
AAPL   112.48 (+3.94%)
MSFT   207.70 (+2.22%)
FB   254.95 (+2.17%)
GOOGL   1,441.99 (+1.34%)
AMZN   3,094.00 (+2.46%)
TSLA   407.87 (+5.18%)
NVDA   514.87 (+4.24%)
BABA   270.64 (+0.34%)
CGC   14.13 (-0.98%)
GE   6.11 (+0.83%)
MU   49.10 (-0.75%)
AMD   78.05 (+2.94%)
T   28.03 (-0.04%)
F   6.52 (-2.10%)
ACB   5.03 (-3.27%)
GILD   62.23 (-0.03%)
NFLX   481.88 (+1.86%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.49 (+7.15%)
S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.70 (+2.38%)
AAPL   112.48 (+3.94%)
MSFT   207.70 (+2.22%)
FB   254.95 (+2.17%)
GOOGL   1,441.99 (+1.34%)
AMZN   3,094.00 (+2.46%)
TSLA   407.87 (+5.18%)
NVDA   514.87 (+4.24%)
BABA   270.64 (+0.34%)
CGC   14.13 (-0.98%)
GE   6.11 (+0.83%)
MU   49.10 (-0.75%)
AMD   78.05 (+2.94%)
T   28.03 (-0.04%)
F   6.52 (-2.10%)
ACB   5.03 (-3.27%)
GILD   62.23 (-0.03%)
NFLX   481.88 (+1.86%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.49 (+7.15%)
S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.70 (+2.38%)
AAPL   112.48 (+3.94%)
MSFT   207.70 (+2.22%)
FB   254.95 (+2.17%)
GOOGL   1,441.99 (+1.34%)
AMZN   3,094.00 (+2.46%)
TSLA   407.87 (+5.18%)
NVDA   514.87 (+4.24%)
BABA   270.64 (+0.34%)
CGC   14.13 (-0.98%)
GE   6.11 (+0.83%)
MU   49.10 (-0.75%)
AMD   78.05 (+2.94%)
T   28.03 (-0.04%)
F   6.52 (-2.10%)
ACB   5.03 (-3.27%)
GILD   62.23 (-0.03%)
NFLX   481.88 (+1.86%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.49 (+7.15%)
S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.70 (+2.38%)
AAPL   112.48 (+3.94%)
MSFT   207.70 (+2.22%)
FB   254.95 (+2.17%)
GOOGL   1,441.99 (+1.34%)
AMZN   3,094.00 (+2.46%)
TSLA   407.87 (+5.18%)
NVDA   514.87 (+4.24%)
BABA   270.64 (+0.34%)
CGC   14.13 (-0.98%)
GE   6.11 (+0.83%)
MU   49.10 (-0.75%)
AMD   78.05 (+2.94%)
T   28.03 (-0.04%)
F   6.52 (-2.10%)
ACB   5.03 (-3.27%)
GILD   62.23 (-0.03%)
NFLX   481.88 (+1.86%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.49 (+7.15%)
Log in
NASDAQ:SURF

Surface Oncology Stock Forecast, Price & News

$6.30
+0.28 (+4.65 %)
(As of 09/25/2020 03:58 PM ET)
Add
Compare
Today's Range
$6.04
Now: $6.30
$6.36
50-Day Range
$5.31
MA: $6.30
$7.23
52-Week Range
$1.15
Now: $6.30
$7.75
Volume21,620 shs
Average Volume1.05 million shs
Market Capitalization$251.41 million
P/E RatioN/A
Dividend YieldN/A
Beta2.49
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; and SRF388 targeting interleukin 27. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Read More
Surface Oncology logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.37 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SURF
CUSIPN/A
CIKN/A
Phone617-714-4096

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.36 million
Book Value$2.03 per share

Profitability

Net Income$-54,790,000.00

Miscellaneous

Employees76
Market Cap$251.41 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$6.30
+0.28 (+4.65 %)
(As of 09/25/2020 03:58 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SURF News and Ratings via Email

Sign-up to receive the latest news and ratings for SURF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Surface Oncology (NASDAQ:SURF) Frequently Asked Questions

How has Surface Oncology's stock price been impacted by COVID-19 (Coronavirus)?

Surface Oncology's stock was trading at $2.37 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SURF shares have increased by 165.8% and is now trading at $6.30.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Surface Oncology?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surface Oncology in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Surface Oncology
.

When is Surface Oncology's next earnings date?

Surface Oncology is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Surface Oncology
.

How were Surface Oncology's earnings last quarter?

Surface Oncology Inc (NASDAQ:SURF) announced its earnings results on Tuesday, August, 11th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.02. Surface Oncology had a negative return on equity of 32.89% and a negative net margin of 70.90%.
View Surface Oncology's earnings history
.

What price target have analysts set for SURF?

4 brokerages have issued 1-year target prices for Surface Oncology's shares. Their forecasts range from $9.00 to $12.00. On average, they anticipate Surface Oncology's stock price to reach $10.67 in the next twelve months. This suggests a possible upside of 69.3% from the stock's current price.
View analysts' price targets for Surface Oncology
.

Are investors shorting Surface Oncology?

Surface Oncology saw a drop in short interest in August. As of August 31st, there was short interest totaling 546,300 shares, a drop of 23.7% from the August 15th total of 715,900 shares. Based on an average trading volume of 831,600 shares, the days-to-cover ratio is currently 0.7 days.
View Surface Oncology's Short Interest
.

Who are some of Surface Oncology's key competitors?

What other stocks do shareholders of Surface Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Surface Oncology investors own include Pfizer (PFE), Intel (INTC), Momo (MOMO), NVIDIA (NVDA), Crowdstrike (CRWD), Paypal (PYPL), QUALCOMM (QCOM), Twilio (TWLO), Xilinx (XLNX) and Walt Disney (DIS).

Who are Surface Oncology's key executives?

Surface Oncology's management team includes the following people:
  • Mr. Daniel S. Lynch, Exec. Chairman (Age 61)
  • Mr. J. Jeffrey Goater, CEO, Pres & Director (Age 44)
  • Dr. Vito J. Palombella, Chief Scientific Officer (Age 56)
  • Dr. Robert W. Ross, Chief Medical Officer (Age 45)
  • Ms. Jessica Fees, Sr. VP of Fin. & Bus. Operations and Treasurer (Age 47)

When did Surface Oncology IPO?

(SURF) raised $84 million in an initial public offering (IPO) on Thursday, April 19th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Evercore ISI acted as the underwriters for the IPO.

What is Surface Oncology's stock symbol?

Surface Oncology trades on the NASDAQ under the ticker symbol "SURF."

Who are Surface Oncology's major shareholders?

Surface Oncology's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (7.20%), Avidity Partners Management LP (5.22%), Bridgeway Capital Management Inc. (0.41%), FMR LLC (0.49%), FMR LLC (0.35%) and Two Sigma Advisers LP (0.33%).
View institutional ownership trends for Surface Oncology
.

Which major investors are selling Surface Oncology stock?

SURF stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, and FMR LLC.
View insider buying and selling activity for Surface Oncology
.

Which major investors are buying Surface Oncology stock?

SURF stock was acquired by a variety of institutional investors in the last quarter, including Avidity Partners Management LP, BVF Inc. IL, Two Sigma Advisers LP, Marshall Wace North America L.P., Schonfeld Strategic Advisors LLC, Bridgeway Capital Management Inc., Quantitative Systematic Strategies LLC, and Cornerstone Investment Partners LLC.
View insider buying and selling activity for Surface Oncology
.

How do I buy shares of Surface Oncology?

Shares of SURF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Surface Oncology's stock price today?

One share of SURF stock can currently be purchased for approximately $6.30.

How big of a company is Surface Oncology?

Surface Oncology has a market capitalization of $251.41 million and generates $15.36 million in revenue each year. The company earns $-54,790,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis. Surface Oncology employs 76 workers across the globe.

What is Surface Oncology's official website?

The official website for Surface Oncology is www.surfaceoncology.com.

How can I contact Surface Oncology?

Surface Oncology's mailing address is 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-714-4096 or via email at [email protected]

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.